BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33188070)

  • 1. Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function.
    Brinkhaus M; Douwes RGJ; Bentlage AEH; Temming AR; de Taeye SW; Tammes Buirs M; Gerritsen J; Mok JY; Brasser G; Ligthart PC; van Esch WJE; Verheesen P; de Haard H; Rispens T; Vidarsson G
    J Immunol; 2020 Dec; 205(12):3456-3467. PubMed ID: 33188070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
    Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
    J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering IgG1 Fc Domains That Activate the Complement System.
    Lee CH; Delidakis G
    Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
    Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
    Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
    Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
    Front Immunol; 2018; 9():958. PubMed ID: 29867943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.
    Lagassé HAD; Hengel H; Golding B; Sauna ZE
    AAPS J; 2019 May; 21(4):62. PubMed ID: 31062128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis.
    Bang R; Marnell L; Mold C; Stein MP; Clos KT; Chivington-Buck C; Clos TW
    J Biol Chem; 2005 Jul; 280(26):25095-102. PubMed ID: 15878871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions.
    Baudino L; Nimmerjahn F; Shinohara Y; Furukawa J; Petry F; Verbeek JS; Nishimura S; Ravetch JV; Izui S
    J Immunol; 2008 Sep; 181(6):4107-12. PubMed ID: 18768867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity of human IgG subclasses to mouse Fc gamma receptors.
    Dekkers G; Bentlage AEH; Stegmann TC; Howie HL; Lissenberg-Thunnissen S; Zimring J; Rispens T; Vidarsson G
    MAbs; 2017 Jul; 9(5):767-773. PubMed ID: 28463043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the effector functions of a human IgG1 through engineering of its hinge region.
    Dall'Acqua WF; Cook KE; Damschroder MM; Woods RM; Wu H
    J Immunol; 2006 Jul; 177(2):1129-38. PubMed ID: 16818770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
    Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
    J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
    Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
    J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding.
    Lightle S; Aykent S; Lacher N; Mitaksov V; Wells K; Zobel J; Oliphant T
    Protein Sci; 2010 Apr; 19(4):753-62. PubMed ID: 20120022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors.
    Redpath S; Michaelsen TE; Sandlie I; Clark MR
    Hum Immunol; 1998 Nov; 59(11):720-7. PubMed ID: 9796740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.
    Dekkers G; Treffers L; Plomp R; Bentlage AEH; de Boer M; Koeleman CAM; Lissenberg-Thunnissen SN; Visser R; Brouwer M; Mok JY; Matlung H; van den Berg TK; van Esch WJE; Kuijpers TW; Wouters D; Rispens T; Wuhrer M; Vidarsson G
    Front Immunol; 2017; 8():877. PubMed ID: 28824618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.